SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4257)5/10/2016 5:50:04 PM
From: tktom  Respond to of 4474
 
Biomaven, there was a lot of infrastructure in this deal (135 employees, and a first class lease of the EU headquarters in Switzerland and associate offices throughout the EU), so I'm not sure I could determine the value of Iclusig in the deal.It was very good for Ariad and the shareholders, and the momentum should build further with the ASCO results in June, and the filing of the NDA for Brigatinib in Q3.



To: Biomaven who wrote (4257)5/10/2016 6:19:48 PM
From: Vidpok1  Respond to of 4474
 
a very well structured deal to provide the funding needed to bridge the financing until the 113 approval. After which follows the usual irrational run up at which point a big pharma will overpay to acquire the company. The big pharmas would much rather overpay after the fact. After all 4 billion or 8 billion isnt worth quibbling over.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News